当前位置:首页 > 文献互助 > 互助详情

The Preclinical Discovery and Development of Depemokimab for Severe Eosinophilic Asthma复制

puremagic 29分钟前 4 10 已关闭

DOI:复制

文献链接:复制

其他信息:

M Cazzola, V Patella, R Pagliaro, A Bianco…
Pulmonary …, 2026
Elsevier
Severe eosinophilic asthma is driven by interleukin (IL)-5-mediated type 2 inflammation and frequently requires long-term biologic therapy. Depemokimab was designed to achieve sustained IL-5 neutralization with a twice-yearly dosing schedule, addressing key unmet needs related to treatment burden and adherence. This review summarizes the molecular design, preclinical pharmacology, model-informed drug development (MIDD) strategy, and Phase I-III clinical trial program, and regulatory approvals of depemokimab in asthma and …

互助时间线

2026-09-22 15:27:58 [关闭求助]

楼主puremagic关闭了求助

2026-09-22 15:27:14 [发起求助]